Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

被引：15
|
作者：
Frank I. Scott
Gary R. Lichtenstein
机构：
[1] University of Colorado Anschutz Medical Campus,Crohn’s and Colitis Center, Division of Gastroenterology and Hepatology
[2] Perelman School of Medicine,Gastroenterology Division
[3] University of Pennsylvania,undefined
来源：
Current Treatment Options in Gastroenterology | 2018年 / 16卷 / 1期
关键词：
Biosimilars; Indication extrapolation; Interchangeability; Infliximab; Adalimumab; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis;
D O I：
10.1007/s11938-018-0177-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：147 / 164
页数：17
相关论文
共 50 条
  • [31] Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
    Ali Hakizimana
    Iftikhar Ahmed
    Rachel Russell
    Mark Wright
    Nadeem A Afzal
    World Journal of Gastroenterology, 2017, (25) : 4473 - 4479
  • [32] Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
    Hakizimana, Ali
    Ahmed, Iftikhar
    Russell, Rachel
    Wright, Mark
    Afzal, Nadeem A.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (25) : 4473 - 4479
  • [33] Supporting patients with inflammatory bowel disease
    Dalibon, Pierre
    ACTUALITES PHARMACEUTIQUES, 2015, 54 (545): : 35 - +
  • [34] Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease
    de Chambrun, Guillaume Pineton
    Blanc, Pierre
    Peyrin-Biroulet, Laurent
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (08) : 915 - 927
  • [35] Acne treatment and inflammatory bowel disease: What is the evidence?
    Alikhan, Ali
    Henderson, Gregory P.
    Becker, Lauren
    Sciallis, Gabriel F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 65 (03) : 650 - 654
  • [36] Comment to "Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease"
    Barreiro de Acosta, Manuel
    Katsanos, Konstantinos H.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (11) : 1302 - 1303
  • [37] The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease
    Pineles, David
    Malter, Lisa
    Liang, Peter S.
    Arsuaga, Amy
    Bosworth, Brian
    Hudesman, David P.
    Chang, Shannon
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (10) : 1361 - 1362
  • [38] The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease
    David Pineles
    Lisa Malter
    Peter S. Liang
    Amy Arsuaga
    Brian Bosworth
    David P. Hudesman
    Shannon Chang
    European Journal of Clinical Pharmacology, 2018, 74 : 1361 - 1362
  • [39] Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico
    Mayoral-Zavala, A.
    Esquivel-Aguilar, A.
    del Real-Calzada, C. M.
    Gutierrez-Grobe, Y.
    Ramos-Garcia, J.
    Rocha-Ramirez, J. L.
    Rojas-Illanes, M. F.
    Rubio-Martinez, B.
    Sanchez-Chavez, X.
    Yamamoto-Furusho, J. K.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2018, 83 (04): : 414 - 423
  • [40] Patient Perceptions Regarding the Use of Biosimilars in Inflammatory Bowel Disease
    Pineles, David
    Arsuaga, Amy
    Malter, Lisa B.
    Bosworth, Brian P.
    Hudesman, David P.
    Chang, Shannon
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S418 - S419
12345